J. Symons, S.F.L. van Lelyveld, W. de Spiegelaere, A.M.J. Wensing, J. Drylewicz, A.I.M. Hoepelman, . . . M. Nijhuis. (2017). The CCR5-agonist maraviroc reverses HIV latency, results from ex vivo studies and a randomized placebo controlled clinical trial. Elsevier.
Chicago Style (17th ed.) CitationJ. Symons, et al. The CCR5-agonist Maraviroc Reverses HIV Latency, Results from Ex Vivo Studies and a Randomized Placebo Controlled Clinical Trial. Elsevier, 2017.
MLA (9th ed.) CitationJ. Symons, et al. The CCR5-agonist Maraviroc Reverses HIV Latency, Results from Ex Vivo Studies and a Randomized Placebo Controlled Clinical Trial. Elsevier, 2017.
Warning: These citations may not always be 100% accurate.